Nifty
Sensex
:
:
22957.10
75410.39
-10.55 (-0.05%)
-7.65 (-0.01%)

Pharmaceuticals & Drugs - API

Rating :
39/99

BSE: 524164 | NSE: IOLCP

371.70
24-May-2024
  • Open
  • High
  • Low
  • Previous Close
  •  372.45
  •  374.50
  •  370.00
  •  371.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  98698
  •  366.84
  •  535.90
  •  350.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,179.74
  • 16.21
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,069.61
  • 1.35%
  • 1.35

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.19%
  • 15.74%
  • 30.98%
  • FII
  • DII
  • Others
  • 1.4%
  • 0.08%
  • 3.61%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.68
  • 5.64
  • 4.07

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.99
  • -11.17
  • -17.48

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 45.46
  • -9.97
  • -31.97

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.00
  • 15.08
  • 15.08

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.26
  • 1.51
  • 1.51

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.83
  • 8.28
  • 8.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
503.92
587.21
-14.18%
520.39
523.48
-0.59%
545.30
541.41
0.72%
563.18
565.01
-0.32%
Expenses
454.40
491.91
-7.63%
476.04
480.80
-0.99%
481.10
509.51
-5.58%
490.66
509.22
-3.64%
EBITDA
49.52
95.30
-48.04%
44.35
42.68
3.91%
64.20
31.90
101.25%
72.52
55.79
29.99%
EBIDTM
9.83%
16.23%
8.52%
8.15%
11.77%
5.89%
12.88%
9.87%
Other Income
7.52
8.73
-13.86%
8.38
6.65
26.02%
7.11
5.07
40.24%
7.06
5.16
36.82%
Interest
3.41
4.88
-30.12%
4.30
4.70
-8.51%
4.44
3.51
26.50%
3.95
3.38
16.86%
Depreciation
16.43
12.11
35.67%
16.34
11.75
39.06%
15.69
11.32
38.60%
14.45
10.98
31.60%
PBT
37.20
87.04
-57.26%
32.09
32.88
-2.40%
51.18
22.14
131.17%
61.18
46.59
31.32%
Tax
9.58
22.26
-56.96%
9.01
9.10
-0.99%
13.31
6.23
113.64%
15.32
11.92
28.52%
PAT
27.62
64.78
-57.36%
23.08
23.78
-2.94%
37.87
15.91
138.03%
45.86
34.67
32.28%
PATM
5.48%
11.03%
4.44%
4.54%
6.94%
2.94%
8.14%
6.14%
EPS
4.70
11.03
-57.39%
3.93
4.05
-2.96%
6.45
2.71
138.01%
7.81
5.91
32.15%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 23
Mar 22
Net Sales
2,132.79
2,217.11
2,184.02
Net Sales Growth
-3.80%
1.52%
 
Cost Of Goods Sold
1,396.95
1,547.09
1,570.51
Gross Profit
735.84
670.02
613.51
GP Margin
34.50%
30.22%
28.09%
Total Expenditure
1,902.20
1,991.44
1,925.73
Power & Fuel Cost
-
131.98
78.18
% Of Sales
-
5.95%
3.58%
Employee Cost
-
168.21
141.30
% Of Sales
-
7.59%
6.47%
Manufacturing Exp.
-
43.07
36.86
% Of Sales
-
1.94%
1.69%
General & Admin Exp.
-
6.54
5.12
% Of Sales
-
0.29%
0.23%
Selling & Distn. Exp.
-
61.85
66.84
% Of Sales
-
2.79%
3.06%
Miscellaneous Exp.
-
32.70
26.92
% Of Sales
-
1.47%
1.23%
EBITDA
230.59
225.67
258.29
EBITDA Margin
10.81%
10.18%
11.83%
Other Income
30.07
25.61
32.04
Interest
16.10
16.47
8.29
Depreciation
62.91
46.16
43.26
PBT
181.65
188.65
238.78
Tax
47.22
49.51
57.18
Tax Rate
26.00%
26.24%
25.43%
PAT
134.43
139.14
167.67
PAT before Minority Interest
134.43
139.14
167.67
Minority Interest
0.00
0.00
0.00
PAT Margin
6.30%
6.28%
7.68%
PAT Growth
-3.39%
-17.02%
 
EPS
22.90
23.70
28.56

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 23
Mar 22
Shareholder's Funds
1,507.72
1,392.28
Share Capital
58.71
58.71
Total Reserves
1,449.01
1,333.57
Non-Current Liabilities
58.15
56.62
Secured Loans
0.00
0.00
Unsecured Loans
0.00
0.00
Long Term Provisions
1.65
3.01
Current Liabilities
502.52
575.29
Trade Payables
314.22
409.29
Other Current Liabilities
54.28
54.02
Short Term Borrowings
79.63
42.75
Short Term Provisions
54.39
69.23
Total Liabilities
2,068.39
2,024.19
Net Block
751.81
560.64
Gross Block
995.24
761.99
Accumulated Depreciation
243.43
201.35
Non Current Assets
1,101.74
881.48
Capital Work in Progress
89.64
105.20
Non Current Investment
17.41
0.00
Long Term Loans & Adv.
9.52
10.77
Other Non Current Assets
233.36
204.87
Current Assets
966.65
1,142.71
Current Investments
2.56
2.37
Inventories
325.52
409.89
Sundry Debtors
505.28
469.80
Cash & Bank
21.83
139.99
Other Current Assets
111.46
30.99
Short Term Loans & Adv.
81.60
89.67
Net Current Assets
464.13
567.42
Total Assets
2,068.39
2,024.19

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 23
Mar 22
Cash From Operating Activity
122.27
93.05
PBT
188.65
224.85
Adjustment
44.41
33.12
Changes in Working Capital
-63.69
-102.34
Cash after chg. in Working capital
169.37
155.63
Interest Paid
0.00
0.00
Tax Paid
-47.10
-62.58
Other Direct Exp. Paid
0.00
0.00
Extra & Other Items
0.00
0.00
Cash From Investing Activity
-120.00
-120.52
Net Fixed Assets
-217.16
Net Investments
-17.80
Others
114.96
Cash from Financing Activity
-4.11
-1.64
Net Cash Inflow / Outflow
-1.84
-29.11
Opening Cash & Equivalents
3.23
32.34
Closing Cash & Equivalent
1.39
3.23

Financial Ratios

Standalone /

Consolidated
Description
Mar 23
Mar 22
Book Value (Rs.)
256.81
237.15
ROA
6.80%
8.28%
ROE
9.60%
12.04%
ROCE
13.57%
16.25%
Fixed Asset Turnover
2.52
2.87
Receivable days
80.26
78.51
Inventory Days
60.53
68.50
Payable days
85.35
95.12
Cash Conversion Cycle
55.45
51.89
Total Debt/Equity
0.05
0.03
Interest Cover
12.45
28.12

News Update:


  • IOL Chemicals completes ANVISA GMP audit of 10 manufacturing units without any observation
    19th Mar 2024, 12:30 PM

    The inspection was conducted from March 11, 2024 to March 15, 2024

    Read More
  • IOL Chemicals gets approval for ‘Metformin Hydrochloride’ from CDE in China
    19th Feb 2024, 15:37 PM

    Metformin Hydrochloride is an antidiabetic drug which is used to manage the high blood sugar levels in diabetes patients

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.